Efficacy of prototype porcine circovirus type 2 subunit vaccine in pigs
TT Peng, HY Lee, WZ Huang, JF Lai, ZW Chen, JH Lin, JP Wang
Porcine circovirus type 2 (PCV2) is the etiologic agent of the porcine circovirus-associated disease and post-weaning multi-systemic wasting syndrome that causes great economical loss in swine industry. Previous studies have showed that vaccination is an effective way to control the disease. In this study, PCV2 ORF2 antigen was produced by a prokaryotic expression system and used in the subunit vaccine preparation. All SPF and commercial pigs showed healthy and no adverse effect after immunized by prototype PCV2 subunit vaccines. Significant seroconversion in PCV2 ELISA was observed after secondary immunization in compared to control group. In field trial, the vaccine group had lower viremia levels compared to control group. The results demonstrate the final component of PCV2 subunit vaccine can elicit protective immunity against PCV2 infection both in SPF and commercial pigs. Thus, this novel PCV2 subunit vaccine, may have market potential to serve as a vaccine aimed to improve swine industry.